Home
>
US Stocks
>
Acorda Therapeutics Inc
Acorda Therapeutics Inc
ACOR

Acorda Therapeutics Inc (ACOR)

$4.11.44%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
4.24
Today Low/High
4.07 / 4.28
52 Week Low/High
$2.53 / $9.84
P/E ratio
-0.2586
Market Cap
$34.14M

Company Details

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
Organisation
Acorda Therapeutics Inc
Headquaters
Ardsley, New York, United States
Employees
168
Industry
Health Technology
CEO
Ron Cohen

Discover more

Frequently Asked Questions

What is Acorda Therapeutics Inc (ACOR) share price today?

Can Indians buy Acorda Therapeutics Inc (ACOR) shares?

How can I buy Acorda Therapeutics Inc (ACOR) shares from India?

Can Fractional shares of Acorda Therapeutics Inc (ACOR) be purchased?

What are the documents required to start investing in Acorda Therapeutics Inc (ACOR) stocks?

We are a SEBI registered investement advisor